Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 4/20 | 0.84 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.79 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.79 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.79 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.79 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.79 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.79 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.79 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.79 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.79 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | VDR | P11473 | 2/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.69 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.69 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4326989 | 1.00 | EPHA2 (0.84) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| SCHEMBL4326984 | 1.00 | EPHA2 (0.84) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| SCHEMBL25710302 | 0.91 | EPHA2 (0.76) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| SCHEMBL23061517 | 0.90 | EPHA2 (0.80) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL25021694 | 0.89 | GPBAR1 (1.00) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL5556804 | 0.89 | GPBAR1 (1.00) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL16084677 | 0.89 | GPBAR1 (1.00) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL25023120 | 0.89 | GPBAR1 (1.00) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL22871921 | 0.89 | GPBAR1 (1.00) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL25023044 | 0.89 | GPBAR1 (1.00) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119064590-B | Protein marker combination for screening clinical ineffective recanalization of large vessel occlusive cerebral apoplexy and application thereof | 南京市第一医院 | 2025-05-09 | — | — | CN | claimed |
| WO-2025059543-A1 | EDITING SYSTEMS AND COMPONENTS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2025-03-20 | — | — | WO | claimed |
| US-20250057870-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-02-20 | — | — | US | claimed |
| CN-119360957-A | K-ras and TP53 co-mutant colon cancer patient immune gene prognosis model system | 苏州市立医院 | 2025-01-24 | — | — | CN | claimed |
| CN-119064590-A | Protein marker combination for screening clinical ineffective recanalization of large vessel occlusive cerebral apoplexy and application thereof | 南京市第一医院 | 2024-12-03 | — | — | CN | claimed |
| EP-4455284-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2024-10-30 | — | — | EP | claimed |
| CN-118202049-A | Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application | 苏州瑞博生物技术股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| WO-2024099575-A1 | ARTIFICIAL NUCLEIC ACIDS FOR SITE-DIRECTED EDITING OF A TARGET RNA | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2024-05-16 | — | — | WO | claimed |
| CN-116042770-B | Method and kit for preparing miRNA library in urine and quantifying expression | 苏州京脉生物科技有限公司 | 2023-12-01 | — | — | CN | claimed |
| WO-2023116607-A9 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州瑞博生物技术股份有限公司 | 2023-10-05 | — | — | WO | claimed |
| CN-116042770-A | Method and kit for preparing miRNA library in urine and quantifying expression | 苏州京脉生物科技有限公司 | 2023-05-02 | — | — | CN | claimed |
| WO-2022258476-A1 | ENCAPSULATED QUATERNARY AMMONIUM COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2022-12-15 | — | — | WO | claimed |
| CN-115104029-A | Non-invasive assay for detecting and monitoring systemic inflammation | 伊契洛夫科技有限公司 | 2022-09-23 | — | — | CN | claimed |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-05-26 | — | — | US | disclosed |
| WO-2026102302-A1 | POLYNUCLEOTIDES CONTAINING A MODIFIED 3'-REGION | MODERNATX, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260103703-A1 | siRNA COMPOSITIONS AND METHODS TARGETING ALPHA-SYNUCLEIN NUCLEIC ACIDS | ATALANTA THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20220073924-A1 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2022-03-10 | — | — | US | disclosed |
| WO-2022047148-A1 | CONVERSION OF A BIOLOGICALLY SILENT MIRNA BINDING SMALL MOLECULE TO AN MIRNA DEGRADER | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220042012-A1 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. | 2022-02-10 | — | — | US | disclosed |
| US-20050196443-A1 | Pulsatile release compositions and methods for enhanced intestinal drug absorption | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073924-A1 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | TEK, RNASE1, LDLR | EPHA2 2707/4885GPBAR1 2678/4885HSD17B10 1388/4885 |
| US-20260103703-A1 | siRNA COMPOSITIONS AND METHODS TARGETING ALPHA-SYNUCLEIN NUCLEIC ACIDS | SNCA, SYNCRIP, UPF1 | EPHA2 3938/4885GPBAR1 4356/4885HSD17B10 4286/4885 |
| US-20250057870-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | RPTOR, METTL16, MCTS1 | EPHA2 4079/4885GPBAR1 3088/4885HSD17B10 4301/4885 |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | UPF1, SMN1; SMN2, RNGTT | EPHA2 1495/4885GPBAR1 4006/4885HSD17B10 4756/4885 |
| US-20220042012-A1 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | IGF2BP1, IGF2BP2, IGFBP1 | EPHA2 3258/4885GPBAR1 3565/4885HSD17B10 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.